Atopic Dermatitis is one of the most prevalent disorders in the world, affecting up to 20% of children globally. Currently, there is no clinical device that can assist in the diagnosis or severity assessment of AD. The study was performed on children between 4 months and 3 years of age and aimed at identifying… Nevisense detects skin barrier dysfunction in children with Atopic Dermatitis weiterlesen
„At Bare Dermatology, we strive to provide our patients with the highest standard of care. Nevisense can help us to identify melanoma at an early stage, which is critical for improving patient outcomes. Melanoma is a leading cause of death among skin cancers, but when detected early, it has a nearly 100% cure rate. Our… SciBase initiates pilot with Bare Dermatology to advance skin cancer detection in Texas weiterlesen
Dan was previously Senior Director Commercial Insights, Market Access and Field Reimbursement at Biofrontera Inc., a company focused on the Dermatology market treating actinic keratosis with PDT (Photodynamic Therapy). At Biofrontera Inc., Dan was an instrumental leader in launching the new company in the US market with their first FDA approved drug and device combination… SciBase strengthens US team with experienced Dermatology executive weiterlesen
Pia will join SciBase as CEO on October 1st, 2023. As previously announced on May 15th, Simon Grant resigned from his position as CEO for personal reasons and will remain with the Company until the end of October to fully support the transition. Pia is an exceptionally well-suited candidate to implement SciBase’s strategy in order… SciBase appoints Pia Renaudin as Chief Executive Officer weiterlesen
SciBase has, under Simons leadership, built a foundation for growth by developing two dermatology products with great potential. Many important advancements have been made within the research, development, quality, regulatory, initial sales, and the reimbursement sides of the business. I believe we now have a solid foundation to stand on and, as Simon will remain… Letter from the Chairman of the Board weiterlesen
The Board has initiated the process to recruit a new CEO and will provide an update in due course. Tord Lendau, chairman of the board of SciBase, will take over certain operational parts of the role of CEO during the transition period as Simon Grant will gradually reduce his involvement. As chairman of the board,… Clarification regarding announcement of senior management changes in SciBase weiterlesen
The Board has initiated the process to recruit a new CEO and will provide an update in due course. Tord Lendau, Chairman of the Board of Directors of SciBase, will assume the role of CEO in the interim to ensure a smooth transition. „We thank Simon for his efforts as Managing Director at SciBase. During… SciBase announces changes in senior management weiterlesen
The first quarter in figures Net sales were TSEK 5,149 (4,260), +21%. The loss after tax was TSEK 10,906 (9,736). The loss per share was SEK 0.15 (0.14). The cash flow from current operations was negative in the amount of TSEK 3,751 (10,512). The gross margin was 68.7% (62.8%). Electrode sales volume increased by 16% and were 11,614 (9,982)… Correction of headline in published Interim report January – March 2023 weiterlesen
A pdf-version of the annual report is enclosed to this press-release. A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. For more information, please contact: Michael Colérus, CFO Tel: +46 70 341 34 72 E-mail: Certified Advisor: Vator Securities Tel: +46 580 065 99 Email: The… SciBase publishes the Annual report for 2022 weiterlesen
„We are very pleased with the new fee schedules and more importantly, the levels will be seen as appropriate by clinicians to support the expanded use of the Nevisense test for early melanoma detection at point of care. For SciBase this is a critical decision that paves the way for further US expansion – both… SciBase receives increased US Medicare fee schedules for the Nevisense melanoma test weiterlesen
